Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis | Journal for ImmunoTherapy of Cancer

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

PDF +
Supplementary
Material

Clinical/translational cancer immunotherapy

Original research

Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis

Online download statistics by month:

Online download statistics by month: February 2022 to October 2024

	Abstract	Full	Pdf
Feb 2022	396	407	117
Mar 2022	390	391	185
Apr 2022	236	242	123
May 2022	169	172	59
Jun 2022	167	177	56
Jul 2022	160	161	46
Aug 2022	169	169	45
Sep 2022	163	163	38
Oct 2022	161	165	62
Nov 2022	223	223	39
Dec 2022	247	247	54
Jan 2023	225	225	32
Feb 2023	164	168	39
Mar 2023	165	167	58
Apr 2023	135	137	46
May 2023	192	192	36
Jun 2023	197	198	39
Jul 2023	206	206	46
Aug 2023	229	230	40
Sep 2023	144	144	25
Oct 2023	190	190	32
Nov 2023	236	235	34
Dec 2023	256	257	42
Jan 2024	174	174	32
Feb 2024	278	279	43
Mar 2024	151	151	61
Apr 2024	113	115	48
May 2024	76	76	29
Jun 2024	95	96	34
Jul 2024	155	156	40
Aug 2024	104	101	29
Sep 2024	123	123	31
Oct 2024	121	122	38
Total	6210	6259	1678